Graham Goodrich
Founder & Principal Consultant
Graham Goodrich has spent over 25 years launching and building blockbuster biopharma brands across neurology, respiratory, immunology, and cardiometabolic health. His best-known work was leading the Nurtec ODT launch at Biohaven mid-pandemic. The brand reached category leadership and the migraine franchise was acquired by Pfizer for $11.6B in 2022. Before Biohaven, he ran a $3.5B cardiometabolic portfolio at Boehringer Ingelheim covering Jardiance, Pradaxa, and others. He holds an MBA from Michigan and a BS from Wake Forest University.
Experience
Professional Journey
VP of Cardiometabolic Marketing, Boehringer Ingelheim
Led a portfolio of pre-launch, newly launched, and mature cardiometabolic assets including Jardiance, Tradjenta, Basaglar, and Pradaxa, totaling more than $3.5B in annual net sales.
SVP of Migraine Marketing, Biohaven
Led the commercial launch of Nurtec ODT mid-pandemic, developing the brand strategy, go-to-market model, and promotion plan from the ground up. The brand reached category leadership and the migraine franchise was acquired by Pfizer for $11.6B in 2022.
U.S. Migraine Franchise Lead, Pfizer
Oversaw the migraine business following Pfizer's acquisition of the Biohaven franchise, managing the transition and continued commercial execution of Nurtec ODT across the U.S. market.
Chief Commercial Officer, Apnimed
Joined as CCO in January 2024, bringing commercial leadership and strategy to a company focused on sleep apnea therapeutics.